Abstract
The hypoxia-inducible factor HIF-1 has been shown to be mandatory for the cellular adaptation to hypoxia. In addition, evidence has been provided that HIF-1 can mediate various stress responses and that it may play an important role under inflammatory conditions even independently of hypoxia. HIF-1 is a heterodimer consisting of an α-subunit which is subject to tight regulation, and a β-subunit, also termed ARNT, which appears to be constitutively expressed. In addition to the complex network controlling the cellular content of HIF-1α at the level of protein stability, recent evidence showed that HIF-1α levels can also be regulated at the mRNA level. In fact, transcriptional regulatory networks seem to be an additional way of controlling HIF-1α levels and may open new therapeutic options to modulate HIF-1α also under non-hypoxic conditions.
Keywords: HIF, nuclear factor kappa b, transcription, promoter, reactive oxygen species, hypoxia
Current Pharmaceutical Design
Title: Regulation of HIF-1α at the Transcriptional Level
Volume: 15 Issue: 33
Author(s): Agnes Gorlach
Affiliation:
Keywords: HIF, nuclear factor kappa b, transcription, promoter, reactive oxygen species, hypoxia
Abstract: The hypoxia-inducible factor HIF-1 has been shown to be mandatory for the cellular adaptation to hypoxia. In addition, evidence has been provided that HIF-1 can mediate various stress responses and that it may play an important role under inflammatory conditions even independently of hypoxia. HIF-1 is a heterodimer consisting of an α-subunit which is subject to tight regulation, and a β-subunit, also termed ARNT, which appears to be constitutively expressed. In addition to the complex network controlling the cellular content of HIF-1α at the level of protein stability, recent evidence showed that HIF-1α levels can also be regulated at the mRNA level. In fact, transcriptional regulatory networks seem to be an additional way of controlling HIF-1α levels and may open new therapeutic options to modulate HIF-1α also under non-hypoxic conditions.
Export Options
About this article
Cite this article as:
Gorlach Agnes, Regulation of HIF-1α at the Transcriptional Level, Current Pharmaceutical Design 2009; 15 (33) . https://dx.doi.org/10.2174/138161209789649420
DOI https://dx.doi.org/10.2174/138161209789649420 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cerebrovascular Complications of Diabetes: SGLT-2 Inhibitors as a Promising Future Therapeutics
Current Drug Targets Editorial (Thematic Issue: Mechanistic Biomarkers: The Field for the Development of Non-Pharmaceutical and Pharmaceutical Approaches to Diagnostics, Prevention and Treatment of Chronic Diseases)
Current Pharmaceutical Design Leukotrienes and Atherosclerosis
Current Drug Targets Sympathetic Overactivity in Patients with Chronic Renal Failure - The Culprit of Increased Cardiovascular Mortality?
Current Hypertension Reviews Roles of p38-MAPK in Insulin Resistant Heart: Evidence from Bench to Future Bedside Application
Current Pharmaceutical Design The Right Ventricle: Biologic Insights and Response to Disease
Current Cardiology Reviews Expanding the Therapeutic Potential of Statins by Means of Nanotechnology Enabled Drug Delivery Systems
Current Topics in Medicinal Chemistry From Erythropoietin to Its Peptide Derivatives: Smaller but Stronger
Current Protein & Peptide Science Adrenomedullin as a Potential Therapeutic Agent for Inflammatory Bowel Disease
Current Protein & Peptide Science The Na+/Ca2+ Exchanger Mediates the Effects of Oxidative Stress in Hypertension
Current Hypertension Reviews Bone Marrow Stem Cell Therapy for Myocardial Angiogenesis
Current Vascular Pharmacology Risk Factors for Development of Heart Failure
Current Cardiology Reviews A Diabetes Treatment Strategy to Reduce the Risk of Cardiovascular Events: Clinical Benefits and Potential of Linagliptin
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The Role of Obesity in the Development of Polycystic Ovary Syndrome
Current Pharmaceutical Design Role of Ca2+-Sensitive K+ Currents in Controlling Ventricular Repolarization: Possible Implications for Future Antiarrhytmic Drug Therapy
Current Medicinal Chemistry Effects of Mesenchymal Stromal Cells on Diabetic Cardiomyopathy
Current Pharmaceutical Design MicroRNAs in the Diagnosis and Treatment of Unstable Angina
Current Topics in Medicinal Chemistry Hydrogen Sulfide: From Physiology to Pharmacology
Inflammation & Allergy - Drug Targets (Discontinued) Inflammation in Peripheral Arterial Disease (PAD)
Current Pharmaceutical Design New Advances in the Field of Calcium Channel Antagonists: Cardiovascular Effects and Structure-Activity Relationships
Current Medicinal Chemistry - Cardiovascular & Hematological Agents